Earnings report for TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) is awaited on February, 27., as reported by RTT. Last year’s earnings per share was $-0.37, while now analysts expect change of 2.70 % down from current $-0.38 earnings per share. 26.67 % negative EPS growth is what Wall Street’s sees after $-0.30 reported EPS previous quarter. TCON is touching $1.0076 during the last trading session, after increased 3.88%.TRACON Pharmaceuticals, Inc. has volume of 116,456 shares. Since February 19, 2018 TCON has declined 63.33% and is downtrending. TCON underperformed the S&P500 by 63.33%.

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration , and fibrotic diseases.The firm is worth $30.10 million. The Company’s lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for soft tissue sarcoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; and Phase I/II clinical trials for wet AMD.Last it reported negative earnings. The company's other product candidates comprise TRC102, a small molecule that is in Phase II clinical trials for mesothelioma, Phase II clinical trials for glioblastoma, Phase I clinical trial for solid tumors and lymphomas, as well as Phase I clinical trial for lung cancer; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trials for the treatment prostate cancer.

For more TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) news released briefly go to: Benzinga.com, Benzinga.com, Nasdaq.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “55 Biggest Movers From Yesterday – Benzinga” released on January 23, 2019, “Week Ahead In Biotech: Focus Shifts To Year-End Clinical Trial Results (Dec. 23-29) – Benzinga” on December 23, 2018, “TRACON Pharmaceuticals and I-Mab Biopharma Announce Strategic Partnerships for Multiple Immuno-Oncology Programs – Nasdaq” with a publish date: November 29, 2018, “TRACON Pharmaceuticals (TCON) CEO Charles Theuer on Q2 2018 Results – Earnings Call Transcript – Seeking Alpha” and the last “Investors unmoved with TRACON Pharma’s TRC105 in mid-stage liver cancer study; shares down 7% – Seeking Alpha” with publication date: January 19, 2018.